

# Líder em SaaS de farmacovigilância de rápido crescimento





## Líder em SaaS de farmacovigilância de rápido crescimento

Uma empresa de SaaS nativa da nuvem, de rápido crescimento, com sede em Bangalore e escritórios nos EUA, Reino Unido e Europa, especializada em soluções de TI para farmacovigilância (PV) e ensaios clínicos para o setor global de ciências biológicas. A empresa oferece uma plataforma multifuncional que combina entrada, processamento de casos, envios regulatórios e detecção de sinais, reduzindo os custos de TI em até 70% e o tempo de conformidade em 30%.

Fundada em 2017, a empresa tem uma equipe especializada em domínios com mais de 65 funcionários baseados na Índia e oferece suporte a mais de 100 clientes diretos e mais de 160 clientes finais em mais de 15 países.

### Principais recursos da plataforma

- Banco de dados unificado de PV com AS2 Gateway
- Módulos de admissão da Web, e-mail e MICC
- Processamento de casos, narrativas automáticas, detecção de sinais
- Suporte a E2B R2/R3 e análises em tempo real
- Módulos integrados de CTMS, EDC, eTMF, ePRO, IWRS e eConsent

### Diferenciação

- Automações baseadas em IA para registro, triagem e processamento de casos
- Sistema unificado de ponta a ponta (em comparação com ferramentas fragmentadas em pilhas legadas)
- Ferramentas integradas de conformidade regulatória (por exemplo, envios, relatórios)
- Confiado pelas 3 maiores das 10 maiores empresas farmacêuticas da Índia

### Pegada estratégica

- Forte presença na Índia, nos EUA, no Reino Unido e na Europa em geral

GROSS REVENUE

\$ 3,000,000

EBITDA

\$ 1,000,000

BUSINESS TYPE

Software e SAAS

COUNTRY

Índia

BUSINESS ID

L#20250961

- Incorporado em CROs globais e em expansão por meio de parcerias (por exemplo, Wipro, Persistent, Cognizant)
- Usado ativamente em mais de 250 estudos clínicos

## Visão

- 2025: Automação de fluxos de trabalho de farmacovigilância liderada por IA
- 2030: Tornar-se um dos 10 maiores fornecedores globais de TI para PV, conquistando 30% de participação no mercado

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

*© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.*



[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)